Sector News

Novo Nordisk CEO sees short-term challenges to growth – paper

December 29, 2014
Life sciences
(Reuters) – Novo Nordisk, the world’s biggest insulin maker, is confident about its long-term growth plans but needs to secure approval for its new long-acting insulin Tresiba in the United States, its chief executive said in a newspaper interview on Saturday.
 
“When we look at the long-term plan … we think that we can demonstrate growth, which is near the ten percent per year,” Chief Executive Lars Rebien Sorensen told Danish daily Berlingske. “But it gets a little challenging in the short term, for it assumes, among other things, that we get Tresiba approved in the U.S.”
 
Novo Nordisk’s once-daily insulin Tresiba, the company’s big hope for the future, failed to win U.S. approval last year.
 
“If we gets Tresiba approved in the U.S. I think we will be able to grow on average 10 percent a year over the next five years,” Sorensen said.
 
The company has delivered annual growth of around 10 percent over the last decade but challenges in the United States have increased, he said.
 
“The question is how many new generations of insulin … can be developed,” he told the newspaper.
 
Sorenson pointed to competition in diabetes treatments from rivals such as Sanofi and Eli Lilly. (Reporting by Ole Mikkelsen. Editing by Jane Merriman)

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach